Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

This publication has 22 references indexed in Scilit:

• Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis
  The Lancet, 2006
• Worldwide burden of gynaecological cancer: The size of the problem
  Best Practice & Research Clinical Obstetrics & Gynaecology, 2005
• Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04
  Vaccine, 2004
• A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV‐16/18 vaccine
  International Journal of Cancer, 2003
• Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer
  New England Journal of Medicine, 2003
• Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis
  British Journal of Cancer, 2003
• A Controlled Trial of a Human Papillomavirus Type 16 Vaccine
  New England Journal of Medicine, 2002
• 2001 Consensus Guidelines for the Management of Women With Cervical Cytological Abnormalities
  JAMA, 2002
• Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus‐like particles in colombian women with invasive cervical cancer
  International Journal of Cancer, 2001
• Seroreactivity to Human Papillomavirus Types 16, 18, 31, and 45 Virus‐Like Particles in a Case‐Control Study of Cervical Squamous Intraepithelial Lesions
  The Journal of Infectious Diseases, 1999